The Use of HPLC as a Tool for Neonatal Cord Blood Screening of haemoglobinopathy

A validation study

A. Al-Madhani, Anil Pathare, S. Al Zadjali, M. Al Rawahi, I. Al-Nabhani, salam alkindi

Research output: Contribution to journalArticle

Abstract

Background: Newborn cord blood screening identifies infants with underlying haemoglobinopathies before they develop the characteristic symptoms or sequelae. Aims: This study was performed to validate the interpretation high-performance chromatography (HPLC) along with complete blood count (CBC) results as a tool for universal neonatal screening of hemoglobin disorders in Oman. Methods: HPLC and CBC data on subjects who participated in the National Neonatal screening program at birth were obtained from archival records. The results recorded at birth were compared with a second study performed on the same subjects, after approval from the local medical research and ethics committee. Results: Only 290 subjects from amongst the original cohort of 3740 newborns could be recalled between April 2010 to March 2011, to repeat HPLC and CBC, as well as perform confirmatory DNA studies, wherever necessary. All these subjects had been documented to show an initial abnormal result. 31 cases who had no HbA at birth on HPLC were confirmed as either homozygous β-thalassaemia major (n=5 subjects) or homozygous sickle cell anemia (n=26 subjects) by appropriate DNA analysis. Additionally, amongst 151 subjects, 72 subjects were studied in the initial study by Hb Bart's quantitation using the alpha thalassaemia short program at birth. In this cohort, 42 subjects with Hb Bart's >1% at birth could be confirmed as having either deletional or non-deletional thalassaemia by GAP PCR studies. No case of HbH was detected in this cohort. Further, carrier status for structural hemoglobin variants (HbS, HbC, HbD, HbE) (n=67) and beta thalassaemia allele with low HbA at birth (n=29 out of 41) were confirmed by relevant molecular studies. Conclusions: The study validated the earlier observation by 100% concordance with the results of CBC and HPLC. Presence of Hb Bart's at birth does not always mean the presence of alpha thalassemia, as subjects with Hb Bart's below 1% by quantitation, were shown to be normal by molecular studies.

Original languageEnglish
Article numbere2019005
JournalMediterranean Journal of Hematology and Infectious Diseases
Volume11
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Hemoglobinopathies
Validation Studies
Fetal Blood
High Pressure Liquid Chromatography
Parturition
Blood Cell Count
alpha-Thalassemia
Neonatal Screening
beta-Thalassemia
Hemoglobins
Newborn Infant
Oman
Medical Ethics
Thalassemia
Research Ethics Committees
DNA
Sickle Cell Anemia
Biomedical Research
Chromatography
Alleles

Keywords

  • Haemoglobinopathy
  • HPLC validation
  • Neonatal
  • Screening
  • Sickle cell disease
  • Thalassaemia

ASJC Scopus subject areas

  • Hematology
  • Infectious Diseases

Cite this

The Use of HPLC as a Tool for Neonatal Cord Blood Screening of haemoglobinopathy : A validation study. / Al-Madhani, A.; Pathare, Anil; Al Zadjali, S.; Al Rawahi, M.; Al-Nabhani, I.; alkindi, salam.

In: Mediterranean Journal of Hematology and Infectious Diseases, Vol. 11, No. 1, e2019005, 01.01.2019.

Research output: Contribution to journalArticle

@article{9d14dddc81b2460bb745396a8bd71bcf,
title = "The Use of HPLC as a Tool for Neonatal Cord Blood Screening of haemoglobinopathy: A validation study",
abstract = "Background: Newborn cord blood screening identifies infants with underlying haemoglobinopathies before they develop the characteristic symptoms or sequelae. Aims: This study was performed to validate the interpretation high-performance chromatography (HPLC) along with complete blood count (CBC) results as a tool for universal neonatal screening of hemoglobin disorders in Oman. Methods: HPLC and CBC data on subjects who participated in the National Neonatal screening program at birth were obtained from archival records. The results recorded at birth were compared with a second study performed on the same subjects, after approval from the local medical research and ethics committee. Results: Only 290 subjects from amongst the original cohort of 3740 newborns could be recalled between April 2010 to March 2011, to repeat HPLC and CBC, as well as perform confirmatory DNA studies, wherever necessary. All these subjects had been documented to show an initial abnormal result. 31 cases who had no HbA at birth on HPLC were confirmed as either homozygous β-thalassaemia major (n=5 subjects) or homozygous sickle cell anemia (n=26 subjects) by appropriate DNA analysis. Additionally, amongst 151 subjects, 72 subjects were studied in the initial study by Hb Bart's quantitation using the alpha thalassaemia short program at birth. In this cohort, 42 subjects with Hb Bart's >1{\%} at birth could be confirmed as having either deletional or non-deletional thalassaemia by GAP PCR studies. No case of HbH was detected in this cohort. Further, carrier status for structural hemoglobin variants (HbS, HbC, HbD, HbE) (n=67) and beta thalassaemia allele with low HbA at birth (n=29 out of 41) were confirmed by relevant molecular studies. Conclusions: The study validated the earlier observation by 100{\%} concordance with the results of CBC and HPLC. Presence of Hb Bart's at birth does not always mean the presence of alpha thalassemia, as subjects with Hb Bart's below 1{\%} by quantitation, were shown to be normal by molecular studies.",
keywords = "Haemoglobinopathy, HPLC validation, Neonatal, Screening, Sickle cell disease, Thalassaemia",
author = "A. Al-Madhani and Anil Pathare and {Al Zadjali}, S. and {Al Rawahi}, M. and I. Al-Nabhani and salam alkindi",
year = "2019",
month = "1",
day = "1",
doi = "10.4084/mjhid.2019.005",
language = "English",
volume = "11",
journal = "Mediterranean Journal of Hematology and Infectious Diseases",
issn = "2035-3006",
publisher = "Universita Cattolica del Sacro Cuore",
number = "1",

}

TY - JOUR

T1 - The Use of HPLC as a Tool for Neonatal Cord Blood Screening of haemoglobinopathy

T2 - A validation study

AU - Al-Madhani, A.

AU - Pathare, Anil

AU - Al Zadjali, S.

AU - Al Rawahi, M.

AU - Al-Nabhani, I.

AU - alkindi, salam

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Newborn cord blood screening identifies infants with underlying haemoglobinopathies before they develop the characteristic symptoms or sequelae. Aims: This study was performed to validate the interpretation high-performance chromatography (HPLC) along with complete blood count (CBC) results as a tool for universal neonatal screening of hemoglobin disorders in Oman. Methods: HPLC and CBC data on subjects who participated in the National Neonatal screening program at birth were obtained from archival records. The results recorded at birth were compared with a second study performed on the same subjects, after approval from the local medical research and ethics committee. Results: Only 290 subjects from amongst the original cohort of 3740 newborns could be recalled between April 2010 to March 2011, to repeat HPLC and CBC, as well as perform confirmatory DNA studies, wherever necessary. All these subjects had been documented to show an initial abnormal result. 31 cases who had no HbA at birth on HPLC were confirmed as either homozygous β-thalassaemia major (n=5 subjects) or homozygous sickle cell anemia (n=26 subjects) by appropriate DNA analysis. Additionally, amongst 151 subjects, 72 subjects were studied in the initial study by Hb Bart's quantitation using the alpha thalassaemia short program at birth. In this cohort, 42 subjects with Hb Bart's >1% at birth could be confirmed as having either deletional or non-deletional thalassaemia by GAP PCR studies. No case of HbH was detected in this cohort. Further, carrier status for structural hemoglobin variants (HbS, HbC, HbD, HbE) (n=67) and beta thalassaemia allele with low HbA at birth (n=29 out of 41) were confirmed by relevant molecular studies. Conclusions: The study validated the earlier observation by 100% concordance with the results of CBC and HPLC. Presence of Hb Bart's at birth does not always mean the presence of alpha thalassemia, as subjects with Hb Bart's below 1% by quantitation, were shown to be normal by molecular studies.

AB - Background: Newborn cord blood screening identifies infants with underlying haemoglobinopathies before they develop the characteristic symptoms or sequelae. Aims: This study was performed to validate the interpretation high-performance chromatography (HPLC) along with complete blood count (CBC) results as a tool for universal neonatal screening of hemoglobin disorders in Oman. Methods: HPLC and CBC data on subjects who participated in the National Neonatal screening program at birth were obtained from archival records. The results recorded at birth were compared with a second study performed on the same subjects, after approval from the local medical research and ethics committee. Results: Only 290 subjects from amongst the original cohort of 3740 newborns could be recalled between April 2010 to March 2011, to repeat HPLC and CBC, as well as perform confirmatory DNA studies, wherever necessary. All these subjects had been documented to show an initial abnormal result. 31 cases who had no HbA at birth on HPLC were confirmed as either homozygous β-thalassaemia major (n=5 subjects) or homozygous sickle cell anemia (n=26 subjects) by appropriate DNA analysis. Additionally, amongst 151 subjects, 72 subjects were studied in the initial study by Hb Bart's quantitation using the alpha thalassaemia short program at birth. In this cohort, 42 subjects with Hb Bart's >1% at birth could be confirmed as having either deletional or non-deletional thalassaemia by GAP PCR studies. No case of HbH was detected in this cohort. Further, carrier status for structural hemoglobin variants (HbS, HbC, HbD, HbE) (n=67) and beta thalassaemia allele with low HbA at birth (n=29 out of 41) were confirmed by relevant molecular studies. Conclusions: The study validated the earlier observation by 100% concordance with the results of CBC and HPLC. Presence of Hb Bart's at birth does not always mean the presence of alpha thalassemia, as subjects with Hb Bart's below 1% by quantitation, were shown to be normal by molecular studies.

KW - Haemoglobinopathy

KW - HPLC validation

KW - Neonatal

KW - Screening

KW - Sickle cell disease

KW - Thalassaemia

UR - http://www.scopus.com/inward/record.url?scp=85061244610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061244610&partnerID=8YFLogxK

U2 - 10.4084/mjhid.2019.005

DO - 10.4084/mjhid.2019.005

M3 - Article

VL - 11

JO - Mediterranean Journal of Hematology and Infectious Diseases

JF - Mediterranean Journal of Hematology and Infectious Diseases

SN - 2035-3006

IS - 1

M1 - e2019005

ER -